Identification of new biomarkers for Down's syndrome in maternal plasma

Journal of Proteomics

Volumn 75, Issue 9, 2012, Pages 2621-2628

  Heywood, Wendy ^a   Mills, Kevin ^a   Wang, Darrell ^a   Hogg, Julie ^b   Madgett, Tracey E ^c   Avent, Neil D ^c   S Chitty, Lyn ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Biomarker; C1 plasma inhibitor; Down's syndrome; Mass spectrometry; Prenatal screening and diagnosis; Serum amyloid P

Indexed keywords

COMPLEMENT COMPONENT C3A; PREALBUMIN; SERUM AMYLOID P;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMAN; MATERNAL PLASMA; NUCLEOTIDE SEQUENCE; PREGNANCY; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING;

BIOLOGICAL MARKERS; COMPLEMENT C1 INHIBITOR PROTEIN; DOWN SYNDROME; FEMALE; HUMANS; PREALBUMIN; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; SERUM AMYLOID P-COMPONENT; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UP-REGULATION;

EID: 84860439029     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.03.007     Document Type: Article

References (29)

1. Fetal Anomaly Screening Programme Combined screening implementation data 2010, http://fetalanomaly.screening.nhs.uk/meetingthestandard.
2. Nicolaides K.H. Screening for fetal aneuploidies at 11 to 13weeks. Prenat Diagn 2011, 31:7-15.
3. Mujezinovic F., Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007, 110:687-694.
4. Chitty L.S., van der Schoot C.E., Hahn S., Avent N.D. SAFE-the special non-invasive advances in fetal and neonatal evaluation network: aims and achievements. Prenat Diagn 2008, 28:83-88.
5. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996, 68:850-858.
6. Mills P.B., Mills K., Johnson A.W., Clayton P.T., Winchester B.G. Analysis by matrix assisted laser desorption/ionisation-time of flight mass spectrometry of the post-translational modifications of alpha 1-antitrypsin isoforms separated by two-dimensional polyacrylamide gel electrophoresis. Proteomics 2001, 1:778-786.
7. Bennett K., Callard R., Heywood W., Harper J., Jayakumar A., Clayman G.L., et al. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI. J Proteome Res 2010, 9:4289-4294.
8. Girardi G., Salmon J.B. The role of complement in pregnancy and fetal loss. Autoimmunity 2003, 36:19-26.
9. Girardi G., Bulla R., Salmon J.E., Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 2006, 43:68-77.
10. Hook E.B., Mutton D.E., Ide R., Alberman E., Bobrow M. The natural history of Down syndrome conceptuses diagnosed prenatally that are not electively terminated. Am J Hum Genet 1995, 57:875-881.
11. Nagalla S.R., Canick J.A., Jacob T., Schneider K.A., Reddy A.P., Thomas A., et al. Proteomic analysis of maternal serum in Down syndrome: identification of novel protein biomarkers. J Proteome Res 2007, 6:1245-1257.
12. Kolialexi A., Tsangaris G.T., Papantoniou N., Anagnostopoulos A.K., Vougas K., Bagiokos V., et al. Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenat Diagn 2008, 28:691-698.
13. Kolla V., Jeno P., Moes S., Tercanli S., Lapaire O., Choolani M., et al. Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ). J Biomed Biotechnol 2010, 2010:952047.
14. Moore L.E., Fung E.T., McGuire M., Rabkin C.C., Molinaro A., Wang Z., et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006, 15:1641-1646.
15. Liu L., Wang J., Liu B., Dai S., Wang X., Chen J., et al. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem 2008, 104:745-755.
16. Gericke B., Raila J., Sehouli J., Haebel S., Konsgen D., Mustea A., et al. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer 2005, 5:133.
17. Colombo G., Milzani A., Colombo R., Dalle-Donne I. Protein S-glutathionylation and S-cysteinylation. Biomarkers for Antioxidant Defense and Oxidative Damage: Principles and Practical Applications 2010, Wiley-Blackwell, Oxford, UK. G. Aldini, K.-J. Yeum, E. Niki, R.M. Russell (Eds.).
18. Toescu V., Nuttall S.L., Martin U., Kendall M.J., Dunne F. Oxidative stress and normal pregnancy. Clin Endocrinol (Oxf) 2002, 57:609-613.
19. Makedou K., Kourtis A., Gkiomisi A., Toulis K.A., Mouzaki M., Anastasilakis A.D., et al. Oxidized low-density lipoprotein and adiponectin levels in pregnancy. Gynecol Endocrinol 2011, 27:1070-1073.
20. Morris J.M., Gopaul N.K., Endresen M.J., Knight M., Linton E.A., Dhir S., et al. Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia. Br J Obstet Gynaecol 1998, 105:1195-1199.
21. Tennent G.A., Lovat L.B., Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995, 92:4299-4303.
22. Ying S.C., Gewurz A.T., Jiang H., Gewurz H. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J Immunol 1993, 150:169-176.
23. Hicks P.S., Saunero-Nava L., Du Clos T.W., Mold C. Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol 1992, 149:3689-3694.
24. Andersen O., Vilsgaard R.K., Juul S.I., Jonson G., Holm N.E., Svehag S.E. Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro. Scand J Immunol 1997, 46:331-337.
25. de Haas C.J., van der Tol M.E., Van Kessel K.P., Verhoef J., Van Strijp J.A. A synthetic lipopolysaccharide-binding peptide based on amino acids 27-39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood. J Immunol 1998, 161:3607-3615.
26. Pepys M.B., Booth S.E., Tennent G.A., Butler P.J., Williams D.G. Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 1994, 97:152-157.
27. Voss A., Nielsen E.H., Svehag S.E., Junker P. Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. Inverse association with anti-dsDNA antibodies. J Rheumatol 2008, 35:625-630.
28. Bianchi D.W., Williams J.M., Sullivan L.M., Hanson F.W., Klinger K.W., Shuber A.P. PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies. Am J Hum Genet 1997, 61:822-829.
29. Lo Y.M., Lau T.K., Zhang J., Leung T.N., Chang A.M., Hjelm N.M., et al. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin Chem 1999, 45:1747-1751.